UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 22, 2013 (May 21, 2013)

PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

001-31392
 
98-0351734
(Commission File Number)
 
(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel
 
31905
(Address of Principal Executive Offices)
 
(Zip Code)

011 972 74 710 7171
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the “Company”), held its annual meeting of stockholders on May 21, 2013. The results of the stockholder voting at the annual meeting are set forth below.

Stockholders voted on the matters set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name
 
For
   
Against
   
Abstain
   
Broker Non-Votes
 
                         
Zami Aberman
   
10,524,983
     
1,693,895
     
32,411
     
16,259,162
 
                                 
Israel Ben-Yoram
   
12,072,682
     
75,845
     
102,762
     
16,259,162
 
                                 
Isaac Braun
   
12,075,388
     
74,420
     
101,481
     
16,259,162
 
                                 
Mark Germain
   
12,057,290
     
92,518
     
101,481
     
16,259,162
 
                                 
Moria Kwiat
   
12,017,624
     
129,784
     
103,881
     
16,259,162
 
                                 
Hava Meretzki
   
12,004,820
     
170,707
     
75,762
     
16,259,162
 
                                 
Nachum Rosman
   
12,062,603
     
87,245
     
101,441
     
16,259,162
 
                                 
Doron Shorrer
   
12,041,363
     
118,197
     
91,729
     
16,259,162
 

Proposal No. 2 — Advisory Vote on the Compensation of our Named Executive Officers

For
   
Against
   
Abstain
   
Broker Non-Votes
 
                     
 
10,264,977
     
1,834,739
     
151,573
     
16,259,162
 

Proposal No. 3 — Advisory Vote on the Frequency of the Advisory Vote on Compensation of our Named Executive Officers

1 Year
   
2 Years
   
3 Years
   
Abstain
   
Broker Non-Votes
 
                           
  3,296,595      
7,492,304
     
1,109,624
     
352,766
     
16,259,162
 

Proposal No. 4 — Ratification of the Selection of Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global, as Independent Registered Public Accounting Firm of the Company for the Fiscal Year Ending June 30, 2013

For
   
Against
   
Abstain
   
Broker
Non-Votes
 
                     
 
27,754,826
     
224,670
     
530,955
   
-
 
 
The results reported above are final voting results.
 
In accordance with the stockholder voting results, in which every “Two Years” received the highest number of votes cast on the frequency proposal, and our Board of Directors’ recommendation in the proxy statement for the 2013 annual meeting of stockholders, our Board of Directors has determined that future stockholder advisory (non-binding) votes on the compensation of our named executive officers will occur every two years. Accordingly, the next stockholder advisory (non-binding) vote on executive compensation will be held at our 2015 annual meeting of stockholders.

 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
 
     
Date: May 22, 2013
By:
/s/ Yaky Yanay
 
 
Name:
 Yaky Yanay
 
 
Title:
Executive Vice President,
Chief Financial Officer and Secretary